ZYDUS LIFESCIENCES FINANCIAL RESULTS
Amfi stock classification: BHEL, 6 more stocks to become largecaps in H2CY2024. Check m-cap cut-off
Based on average market capitalization from January to June 2024, seven stocks are poised to join the large-cap category. The list includes two-wheeler giant Hero MotoCorp, state-run companies BHEL and NHPC, along with Zydus Lifesciences, JSW Energy, Bosch, and Cummins India.
Quant Mutual Fund added 27 stocks to its portfolio in May. Do you own any?
Quant Mutual Fund is under Sebi inquiry for suspected front-running, leading to search and seizure operations in Mumbai and Hyderabad.
Q4 results: Stable costs boost India Inc. profits
Steady costs and firm domestic demand supported corporate performance in the March quarter.
Amfi stock classification: Multibagger midcaps NHPC, BHEL, 5 others likely to turn largecaps
Existing largecaps likeICICI Prudential Life Insurance Company, ICICI Lombard General Insurance Company, Polycab India, SRF, Marico, SBI Cards & Payment Services and Berger Paints are likely to lose their tags.
Suzlon Energy, PB Fintech, NHPC among 19 midcap additions by mutual funds in May
Top mutual funds like SBI Mutual Fund, Axis MF, Nippon India MF bought 19 midcap stocks, including Suzlon Energy, NHPC, and PB Fintech, the parent of online insurance aggregator Policybazaar.
Parag Parikh Flexi Cap Fund increases stake in ITC, HDFC and Kotak
Parag Parikh Flexi Cap Fund increases stake in ITC, HDFC, and Kotak while making exits from Bajaj Finance and HUL in May. The largest flexi cap fund manages assets worth Rs 66,383 crore and is benchmarked against Nifty 500- TRI.
- Go To Page 1
Accumulate Zydus Lifesciences, target price Rs 1196: Geojit Financial Services
Zydus Lifesciences Ltd., incorporated in the year 1995, is a Large Cap company (having a market cap of Rs 105126.30 Crore) operating in Pharmaceuticals sector.
Zydus Lifesciences Q4 Results: Drug makers posts threefold YoY jump in net profit to Rs 1,182 crore
Zydus Lifesciences on Friday reported Rs 1,182 crore net profit in Q4FY24, a threefold year-on-year (YoY) jump led by growth in US, India, Europe and emerging market sales.
Zydus Q4 Results: Net profit surges 4-fold to Rs 1,182 crore; revenue at Rs 5,534 cr
Zydus Lifesciences on Friday said its consolidated net profit surged four-fold to Rs 1,182 crore for the fourth quarter ended March 31, 2024 on higher sales. The drug firm had reported a net profit of Rs 297 crore in the January-March quarter of the 2022-23 fiscal.
Amfi stock classification: Multibaggers BHEL, NHPC, 5 more stocks to likely turn largecaps
In the upcoming Amfi Semi-Annual Categorisation for the second half of 2024, seven stocks, including Hero MotoCorp and BHEL, are poised to move to the large-cap category from mid-cap. Stellar rallies have propelled their returns over the past year.
Zydus Wellness shares rally nearly 4% after reporting PAT at Rs 150 crore; declares Rs 5 dividend
Zydus Wellness shares surged 3.8% on BSE, reaching a new 52-week high at Rs 1,750.20 following a 4% YoY rise in Q4 FY24 profit after tax to Rs 150.3 crore. The board announced a dividend of Rs 5 per share, with the record date set for July 19.
Market Trading Guide: SBI, Zydus Lifesciences among 5 stock recommendations for Tuesday
Indian shares closed flat amidst volatile trading on Monday, with declines in state-owned lenders offsetting gains in IT stocks fueled by growing expectations of US rate cuts. The S&P BSE Sensex closed 0.02% higher at 73,895, while the NSE Nifty50 index ended below 22,450 level. "The Index has formed a small red candle but on the downside, the zone of 22,330-22,380 will act as a strong support while the higher side seems to be capped at 22,580," said Aditya Gaggar, Director of Progressive Shares. Here are 5 stock recommendations for Tuesday:
Amfi stock classification: NHPC, Hero Motocorp may become largecaps; SRF, SBI Card could shed tag
The likely move comes on the back of a strong rally over the last one year. BHEL, JSW and NHPC have delivered multibagger returns of 239%, 135% and 110%, respectively. Zydus, Hero Moto, Samvardhana and Bosh have yielded between 85 and 48% returns during the period.
PPFAS Flexicap Fund bought 8.8 lakh shares of ITC amid BAT stake sale in March
In February, PPFAS had around 30 stocks in its equity portfolio which declined to 29 in March.
Vedanta, DLF among 5 stocks with long buildup
A "long buildup" occurs when there is an increase in open interest and trading volumes alongside a rise in the price of the underlying stock in the Futures and Options segment, indicating a bullish trend in the market. In Friday's trading session, five stocks experienced a buildup of fresh long positions. Here's the list:
MSCI May rejig to trigger $3.2 billion inflows into 17 stocks
MSCI will announce the changes in the constituents of the MSCI global standard indices on May 14, while the changes will take place on May 31.
Zydus Lifesciences net profit jumps 27% in Q3FY24, announced buyback
Zydus Lifesciences on Tuesday reported Rs 789.6 crore net profit in Q3FY24, a year-on-year (YoY) jump of 27% led by growth in India, Europe and emerging market formulation sales.
Zydus Lifesciences Q3 Results: Firm beats profit estimates; approves shares buyback
Indian generic drugmaker Zydus Lifesciences reported a bigger-than-expected rise in third-quarter profit on Friday, driven by strong sales in its domestic and overseas markets.
TCS, Airtel among 5 stocks with long buildup
A long buildup is when there is a rise in open interest and volumes along with an increase in the price of the underlying stock in the Futures and Options segment. The long buildup is the occurrence of a long (buying) trend in the share market. In Tuesday's trading session, five stocks witnessed a build of fresh long positions. Here's the list:
Sectoral tailwinds and stronger balance sheets: 5 largecap stocks with right mix of two important ratios
There are some sectors where large players have an edge, because the nature of the business is such that there are phases where ability to stay in the game and cash on the balance sheet matter most. When the tide turns in favor of that sector, these large companies are able to make most of it. One sector which has gone through a phase of realignment of business and readjustment of valuations for many years and has once again come in limelight is the pharma space. Right from ability to deal with USFDA, not rely just on product segment to how to deal with uncertainty of supply chain which is dependent on China, Indian pharma companies have come a long way.
Good for all market conditions: 6 largecap stocks with right mix of RoE & RoCE
There is sunshine all around, better than expected GDP numbers, further decline in oil prices, falling US bond yields and clear indication from RBI that it is in no mood to increase interest rates any further. So while macros are bullish and could not get better, it is time to spend some time in understanding what stocks are you buying and why that stock at this point of time only. Also if one is thinking about increasing the exposure it would be better to stay with large caps as they would be able to weather any storm which might emerge due to any reason.
Glenmark Pharma Q2 Results: Co posts loss on exceptional legal costs
The company posted a consolidated net loss, from continuing operations, of 2.01 billion rupees ($24.14 million) for the three months ended Sept. 30, from a profit of 1.54 billion rupees a year ago
YES Bank, Apollo Tyres and 7 other mid and small cap stocks surpass 100-day SMA
The stock market witnessed a surge as several mid and smallcap stocks demonstrated remarkable strength by surpassing their 100-Day Simple Moving Average (SMA) on November 8.
Zydus Lifesciences Q2 Results: Firm reports 53% YoY jump in net profit at Rs 801 crore
Revenue from operations rose 9.1% YoY to Rs 4369 crore in Q2FY24 compared to Rs 4006 crore in Q2FY23. On QoQ revenue declined 15%. The earnings before interest, tax, depreciation and ammortisation (EBITDA) increased 40.6% YoY to Rs 1146 crore. On QoQ, EBITDA dropped 23.9%.
Zydus Q2 Results: Profit jumps on strong domestic, US demand
India's generic drug makers, which draw a significant share of revenue from the crucial U.S. market, are recovering from the effects of eroding prices in the largest drug market in the world.
Zydus bets big on proprietary drugs to boost revenue
Sharvil Patel, managing director of Zydus Lifesciences said, half of the research and development (R&D) allocation is geared towards developing new chemical entities (NCEs), biologics and differentiated products. On average, Zydus spends about 8% of its revenue on R&D, which is higher than the industry average of 6%.
In AI age, India Inc gets young on board as independent directors
In a country where millennials make up the largest share of the workforce, India Inc is trying to board young executives as independent directors. “Bringing on young independent directors adds dynamism and new-age thinking to corporate boards. It also helps in bridging the age diversity gap on the boards of companies,” said Parikh.
Zydus Lifesciences Q1 Results: Net profit doubles to Rs 1,087 crore, revenue jumps 30%
US business grew by 57% YoY at Rs 2454 crores. India branded formulations grew by almost 12%, excluding impact of NLEM related price cut affecting some key products
Zydus Lifesciences Q1 Results: Profit more than doubles on US sales growth
Its U.S formulations business saw a revenue growth of 57.4% to 24.54 billion rupees, while India formulations grew by 9.1% to 12.27 billion rupees. India and U.S. sales make up 38% and 48% of Zydus' total revenue, respectively.
Load More
